Which patients with aggressive B-cell NHL do not qualify for CAR-T?

During the 4th European CAR T-cell Meeting the Lymphoma Hub was pleased to speak with, Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain, ES. We asked, Which patients with aggressive B-cell NHL do not qualify for CAR-T? We also asked, Is CAR-T a new standard-of-care for aggressive B-Cell non-hodgkins lymphoma (NHL)

Sureda begins by outlining the results of two clinical trials from ASH 2021 that compared SoC followed by allo-HSCT with anti-CD19 CAR T-cell therapy. Sureda expressed that those patients deemed ineligible for treatment with CAR T-cell therapy in these trials would generally not qualify for CAR-T. She goes on to outline a third, less defined group of patients which might not qualify that achieve a complete remission with second line chemotherapy.

Finally Sureda hypothesizes a change in the standard of care for patients with second line aggressive NHL.